microRNAs  Epigenetic players in cancer and aging

Nirmaladevi, Ramalingam

doi:10.2741/s525

Cited by 28 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies agree on the usage of miRNAs as a diagnostic marker for many diseases because of their ability to upregulate or downregulate some type of genes. Additionally, according to the previous investigations of MiRNA-155, miRNA-155 can be used as an early diagnostic marker in a variety of diseases [ 16 ]. The approach of this study is to determine its level in spontaneous bacterial peritonitis patient's serum and its effectiveness in combination with miRNA-146b and procalcitonin.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis

El-Hassib¹,

Abo-Elmatty²,

Mesbah³

et al. 2021

TOBIOMJ

View full text Add to dashboard Cite

Background: MircoRNAs are endogenous, small non-coding RNA molecules that have been recognized as important modulators of gene expression. MicroRNA is considered one of the potential biomarkers of infection and inflammation. Our study aims to identify the potential role of miRNA-155, miRNA-146b, and Procalcitonin (PCT) in the early detection of spontaneous bacterial peritonitis in cirrhotic liver patients. miRNA-155 and 146b are molecular biomarkers , while procalcitonin is a serum marker in ascites patients complicated with Spontaneous Bacterial Peritonitis (SBP) . Methods: This study was conducted on 199 patients, 101 of them have ascites complicated with spontaneous bacterial peritonitis, and 98 patients without spontaneous bacterial peritonitis (control group). Ascitic fluid samples were collected from patients with SBP undergoing paracentesis at National Hepatology Institute in Egypt. MicroRNAs were determined in the serum using qPCR (quantitative polymerase chain reaction), while procalcitonin has been assessed in serum samples using ELISA (Enzyme-linked immune assay) technique. Results: Serum levels of miRNA-146b & miRNA-155 were significantly higher (p<0.001) in spontaneous bacterial peritonitis patients (79.2% and 97.0% respectively) than ascites patients (17.3% and 7.1%, respectively). Furthermore, the serum level of procalcitonin was significantly higher (p<0.001) in spontaneous bacterial peritonitis patients than that in ascites patients (68.3% and 27.6%, respectively). Conclusion: miRNA-155, miRNA-146b and procalcitonin can be used as early markers for the detection of SBP in hepatic patients with ascites.

show abstract

Section: Discussionmentioning

confidence: 98%

“…It is one of 15 miRNA that has been reported to be expressed differentially in breast cancer. Additionally, miRNA-155 promotes the development of non-small lung cancer and is found to be commonly expressed in other types of cancer, such as pancreatic cancer [16].…”

Section: Mirnas As Biomarkersmentioning

confidence: 99%

The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis

El-Hassib¹,

Abo-Elmatty²,

Mesbah³

et al. 2021

TOBIOMJ

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that dysregulation of miRNAs not only affects cellular processes associated with carcinogenesis, tumor resistance, invasion, and metastasis but may also have a direct impact on the effectiveness of treatment [ 29 , 30 ]. Among them, there are oncogenic miRNA and tumor suppressor miRNA, which act on tumor suppressor genes and proto-oncogenes, respectively.…”

Section: Discussionmentioning

confidence: 99%

Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies

Liu

Deng

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the mechanism of baicalin intervention in breast cancer based on microRNA microarrays. Methods. The inhibitory rate of baicalin intervention in MCF-7 breast cancer cells was determined by MTT. Then, the miRNA microarrays were used to validate the key microRNAs. After that, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to validate microRNA, hsa-miR-15a, hsa-miR-100, hsa-miR-16, and hsa-miR-7t. Finally, the potential targets of these key microRNAs are predicted by miRWalk, and DAVID was utilized for gene ontology (GO) enrichment analysis and pathway enrichment analysis. Results. Baicalin may inhibit the proliferation of MCF-7 cells in a dose-dependent and time-dependent manner. The concentration of baicalin 150 μmol/L was determined for the subsequent miRNA chip research. A total of 92 upregulated microRNAs and 35 downregulated microRNAs were obtained. The upregulated miRNAs include hsa-miR-6799-5p, hsa-miR-6126, hsa-miR-4792, hsa-miR-6848-5p, hsa-miR-3197, hsa-miR-6779-5p, and hsa-miR -654-5p. The downregulated miRNAs include hsa-miR-3911, hsa-miR-504-5p, hsa-miR-30a-3p, hsa-miR-193b-3p, and hsa-miR-181b-5p. Then, differentially expressed miRNA was verified by qRT-PCR. The results showed that the expression of hsa-miR-15a, hsa-miR-100, hsa-miR-16, and hsa-let-7c was upregulated ( P < 0.05 ), which was consistent with the results of the miRNA microarray. The enrichment analysis showed that baicalin might regulate the DNA-templated proliferation, DNA-templated transcription, p53 signaling pathway, etc., of MCF-7 breast cancer cells through miRNA. Conclusion. Baicalin inhibits the proliferation of breast cancer cells. It may achieve antitumor effects through regulating microRNAs so as to affect the DNA replication (such as cellular response to DNA damage stimulus and DNA binding), RNA transcription (such as regulation of transcription, DNA-templated, transcription from RNA polymerase II promoter, and transcription factor binding), protein synthesis (such as mRNA binding, Golgi apparatus, and protein complex), endocytosis, pathways in cancer, p53 signaling pathway, and so on.

show abstract

“…The drug targets may be peptides, proteins, or nucleic acids. Drugs are classified into three categories (i) biological compounds that target membrane receptors and extracellular proteins (ii) nucleic acids which target mRNA [3,4], (iii) low molecular weight compounds which target receptors or enzymes [5]. These small molecules are mostly preferred because of their low cost and can be delivered easily to the target site.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, it is not possible to screen every target for a drug in the laboratory for both direct and alternative medical approaches [13-16, 18, 19, 26]. Starting from environmental health [7,27], nutritional data [25], to complicated miRNA interaction in health and aging [3,4], the generation of vast data is very common. For example, bio-medical pathway studies, not only provide new insights, but also vast data [13,23,24].…”

Section: Introductionmentioning

confidence: 99%

Approaches for network based drug discovery

Jayachandran

Ilango

Paital

et al. 2021

Front. Biosci. (Schol Ed)

View full text Add to dashboard Cite

Introduction 3. Interaction of drug with target 4. Methods to study drug interaction 4.1 Molecular docking-based method 4.2 Pharmacophore-based method 4.3 Similarity-based method 4.4 Machine learning-based 4.5 Network based methods 5. Drug repositioning 6. Data sources for network construction 7. Side effects nbdd analysis 8. Drug discovery from medicinal plants by nbdds 9. Elucidation of molecular mechanisms by nbdds 10. Protein-protein interaction (PPI) networks 10.1 Analyses of PPI network 10.2 PPI characterization by in silico approaches 11. Integrated network-based methods 12. Conclusions 13. Ethics approval and consent to participate 14. Author contributions 15. Acknowledgment 16. Funding 17. Conflict of interest 18. References

show abstract

microRNAs Epigenetic players in cancer and aging

Cited by 28 publications

References 0 publications

The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis

The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis

Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies

Approaches for network based drug discovery

Contact Info

Product

Resources

About